| A clinical drug development programme to evaluate and compare the safety and efficacy of new regimens of Lifecare's Liposomal Amphotericin b (FUNGISOMETM) against currently accepted therapies for the treatment of Kala Azar; A Phase III, Open Label Randomized Trial of Three Single Dose Treatment regimens of FUNGISOMETM ALONE OR IN Combination with Miltefosine compared with single Dose Treatment regimen of AmBisome for visceral Leishmaniasis in India | Dr. J N Verma, Lifecare Innovations Private Limited, Gurgaon, Haryana (122018) | 2024 | Department of Science and Technology (DST) | Pharmaceutical Sciences |
| Stereoselective Synthesis of Structurally Diverse Sp3-rich Polycyclic Scaffolds: Generation of High valued New Molecular Entities (NMEs) for GPCR Modulators | Dr. Ravindra Kumar, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow, Uttar Pradesh | 2024 | Anusandhan National Research Foundation (ANRF)/Science and Engineering Research Board (SERB) | Pharmaceutical Sciences |
| Dual-targeted novel combination therapy for triple-negative breast cancer | Dr. Shashank Kumar, Central University Of Punjab, Bathinda, Punjab | 2024 | Anusandhan National Research Foundation/ Science and Engineering Research Board | Pharmaceutical Sciences |
| Water-soluble Ru(II) and Pd(II) Porphyrins as Novel Photosensitizers for Photodynamic Therapy | Dr. Tridib Kumar Goswami, Gauhati University, Assam | 2024 | Anusandhan National Research Foundation/ Science and Engineering Research Board | Pharmaceutical Sciences |
| In silico discovery and biological evaluation of potential drug molecules to improve the treatment of Bedaquiline and Delamanid resistance in Mycobacterium tuberculosis. | Dr. Shalini Saxena, University of Hyderabad, Telangana (500046) | 2024 | Department of Science and Technology (DST) | Pharmaceutical Sciences |
| Exploration of Cyclic Diaryliodonium Salts as Biarylating Agents to Generate Medicinally Relevant Biaryl | Dr. Malleswara Rao Kuram, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow, Uttar Pradesh | 2024 | Anusandhan National Research Foundation (ANRF)/Science and Engineering Research Board (SERB) | Pharmaceutical Sciences |
| Multiepitope nanoglycoconjugate vaccine development against Mycobacterium tuberculosis | Dr. Jairam Meena, Indian Institute Of Technology (BHU), Uttar Pradesh | 2024 | Anusandhan National Rsearch Foundation (ANRF)/Science and Engineering Research Board (SERB) | Pharmaceutical Sciences |
| Pharmacological Intervention using α-Klotho with AT1 Receptor Blocker and Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitor against Diabetic Kidney Disease | Prof. Anil Bhanudas Gaikwad, Birla Institute Of Technology And Science (BITS), Pilani, Rajasthan | 2024 | ANRF/SERB | Pharmaceutical Sciences |
| Biopolymeric Porous Carriers Through Assembly of Emulsion Templating and Microfluidics for Controlled Delivery of Drugs and Therapeutics | Dr. Anilkumar Lalchand Yadav, Dr. B R Ambedkar National Institute Of Technology, Jalandhar, Punjab | 2024 | Anusandhan National Research Foundation/ Science and Engineering Research Board | Pharmaceutical Sciences |
| Evaluating the transmission powder X-ray diffraction and multivariate data analysis for quantitative phase identification of Active Pharmaceutical Ingredients (APIs) | Dr. Jagadeesh Babu Nanubolu, CSIR-Indian Institute Of Chemical Technology, Hyderabad, Telangana | 2024 | Anusandhan National Research Foundation (ANRF)/Science and Engineering Research Board (SERB) | Pharmaceutical Sciences |